Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

Menarini Industrie Farmaceutiche Riunite Massachusetts Italy Germany France Switzerland Spain Netherlands United Kingdom Belgium United States of America Austria

This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase.Under the agreement, Menarini Group will be granted global rights to develop and commercialize the asset. The deal includes a $20m upfront payment, and the combined value, including all development, regulatory, and commercial milestones, is over $550 million, followed by tiered royalties.View original content:https://www.prnewswire.co.uk/news-releases/menarini-group-and-insilico-medicine-enter-a-second-exclusive-global-license-agreement-for-an-ai-discovered-preclinical-asset-targeting-high-unmet-needs-in-oncology-302348075.html